Clinical Trials Directory

Trials / Completed

CompletedNCT01962311

Evaluation of Metabolomic Analysis in Early Diagnosis of ALS

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
82 (actual)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This project is expected to answer the question of interest assays of metabolites in the CSF as a tool for early diagnosis and should show whether it is possible or not to use such markers in the blood or urine. These studies should also help shed light on the pathophysiological original early clinical disease. While ALS appears to be more a clinical syndrome that pathophysiological entity unique metabolic abnormalities identified could help identify mechanisms disrupted in which therapeutic interventions will be possible.

Detailed description

A blood test that would allow the diagnosis 1. to reduce the time between the first signs and diagnosis in ALS patients for therapeutic treatment earlier and 2. to exclude rapidly non ALS in their avoiding unnecessary investigations and anxiety of being infected with a terrible prognosis disease. It is currently accepted that neurodegenerative diseases such as ALS begin before the first clinical signs and the patient could benefit from a more efficient care if it was early. Conduct a prospective study with 400 patients. The secondary objectives are: 1. attempt to improve the predictive power of markers assays by adding new parameters 2. to check whether the assayed molecules in other environments more accessible (blood, urine) would provide equivalent diagnostic power of those assayed in the CSF 3. identify metabolic pathways disrupted early that could be related to the pathogenesis of neurodegeneration.

Conditions

Interventions

TypeNameDescription
PROCEDURElumbar puncturelumbar puncture at enrollment in study

Timeline

Start date
2013-02-01
Primary completion
2017-02-01
Completion
2018-02-01
First posted
2013-10-14
Last updated
2019-07-17

Locations

6 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01962311. Inclusion in this directory is not an endorsement.